Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1082

—

bafdf570-c7b9-5cb2-a00d-4b95e92936b7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.541
  • MYC_TARGETS_V1+0.533
  • E2F_TARGETS+0.506
  • G2M_CHECKPOINT+0.453
  • MTORC1_SIGNALING+0.390
  • OXIDATIVE_PHOSPHORYLATION+0.318
  • CHOLESTEROL_HOMEOSTASIS+0.247
  • DNA_REPAIR+0.246
  • ANGIOGENESIS+0.215
  • GLYCOLYSIS+0.214

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.460
  • INTERFERON_GAMMA_RESPONSE-0.344
  • HEME_METABOLISM-0.243
  • ALLOGRAFT_REJECTION-0.232
  • TGF_BETA_SIGNALING-0.228
  • UV_RESPONSE_DN-0.225
  • IL6_JAK_STAT3_SIGNALING-0.189
  • HEDGEHOG_SIGNALING-0.179
  • PROTEIN_SECRETION-0.147
  • WNT_BETA_CATENIN_SIGNALING-0.142

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-22-1012-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.871
2MDT-AP-0426
medullo-epn-umap@date-based
MedMedulloblastoma0.869
356218_S133
lung-landscapes@6
—cohortSQ10.852
4MNG1229
mng-umap@100
——0.839
5MNG883
mng-umap@100
——0.838
6MNG715
mng-umap@100
——0.837
7MNG1117
mng-umap@100
——0.836
8TCGA-BB-A5HY-01A-11R-A28V-07
head-neck@1
——0.824
9BS_74FS6GMW
brain-umap@2
ATRT—0.819
10TCGA-94-8035-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.817

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.541Idelalisib— uncovered
MYC_TARGETS_V10.533Inavolisib— uncovered
E2F_TARGETS0.506Inavolisib— uncovered
G2M_CHECKPOINT0.453Inavolisib— uncovered
MTORC1_SIGNALING0.390Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.318Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.247Remibrutinib— uncovered
DNA_REPAIR0.246Idelalisib— uncovered
ANGIOGENESIS0.215Remibrutinib— uncovered
GLYCOLYSIS0.214Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.202Inavolisib— uncovered
UV_RESPONSE_UP0.192Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.185Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.154Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.138Inavolisib— uncovered
APICAL_JUNCTION0.136Inavolisib— uncovered
PANCREAS_BETA_CELLS0.119Cobimetinib— uncovered
HYPOXIA0.105Idelalisib— uncovered
P53_PATHWAY0.101Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.094Inavolisib— uncovered